{
    "nct_id": "NCT04980872",
    "official_title": "A Multicenter, Open-label, Phase 2, Extension Trial to Study the Long-term Safety in Participants With PROS or Proteus Syndrome Who Are Currently Being Treated With Miransertib in Other Studies",
    "inclusion_criteria": "* Has PROS or PS and has been screened in Study MK-7075-002 (or has been approved by the Sponsor to screen for MK-7075-002) or is currently being treated with miransertib as part of Study MK-7075-002 (NCT03094832) or ArQule's CU/EAP (NCT03317366)\n* For males, agrees to be abstinent from heterosexual intercourse or use contraception unless confirmed to be azoospermic during the study period and for â‰¥90 days after the last dose of study intervention\n* For females, is not pregnant or breastfeeding, and is either not a participant of childbearing potential (POCBP) or is a POCBP and is abstinent or uses a highly effective method of contraception\nHealthy volunteers allowed\nMust have minimum age of 2 Years\nMust have maximum age of 120 Years",
    "exclusion_criteria": "* Has previously discontinued miransertib due to related SAEs or other intolerance of miransertib\n* Has received other investigational agents, if any, that were administered between leaving Study MK-7075-02 or ArQule's CU/EAP and entering this trial\n* Is receiving systemic inhibitors of the mechanistic target of rapamycin (mTOR) pathway (eg, sirolimus, everolimus)\n* Is receiving immunosuppressive therapies\n* Is receiving continuous high dose steroids",
    "miscellaneous_criteria": ""
}